In a phase 3 study, Defencath (taurolidine and heparin) reduced catheter-related bloodstream infections by 71% compared to only heparin. The aqueous-based medication is approved for adult patients with kidney failure who are receiving chronic hemodialysis through a central venous catheter.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
